Cingulate Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Cingulate Inc. (CING) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $586.51 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2026-03-18
- Cingulate Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2024-03-31 was $586.51K.
- Cingulate Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2023-12-31 was $0.00.
- Cingulate Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2023-09-30 was $1.86M.
- Cingulate Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2024 was $586.51K, a 68.51% decline from fiscal 2023.
- Cingulate Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2023 was $1.86M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $586.51K 10-K · filed 2026-03-18 | |||
| 2024-03-31 | $586.51K 10-Q · filed 2025-11-13 | $586.51K derived: sum of 2 quarters · filed 2025-11-13 | $2.45M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.86M derived: sum of 2 quarters · filed 2025-03-27 | $1.86M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $1.86M 10-Q · filed 2024-11-07 | $1.86M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |